Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LipoFufol
- Development stage
- Preclinical
- Lead developer
- Aix-Marseille University
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intraperitoneal, Intravenous
01
Overview
LipoFufol is a triple stealth liposomal formulation of modulated 5-fluorouracil (5-FU) combined with 2'-deoxyinosine and folinic acid (leucovorin). Developed by researchers at Aix-Marseille University, it is designed to improve the efficacy-toxicity balance of 5-FU. The pegylated liposomal delivery system (approximately 120 nm in diameter) optimizes the pharmacokinetic profile of 5-FU by reducing clearance, prolonging half-life, and enhancing accumulation in tumor tissues via the enhanced permeability and retention (EPR) effect. In preclinical models of colorectal and breast cancer, LipoFufol demonstrated superior antiproliferative activity and reduced systemic toxicities, such as neutropenia, compared to free 5-FU.
- Other names
- LipoFuFoltriple stealth liposomal formulation of modulated 5-FU
02
Targets
PNP (Purine nucleoside phosphorylase)TS (Thymidylate synthase)TYMP (Thymidine phosphorylase)DNA
Beyond the preview
Go deeper on LipoFufol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LipoFufol.